. home.aspx

NEWS

home.aspx
   


Leo Lens Pharma Excited to Have Its Lead Asset Ready for Human Clinical Evaluation

June 23, 2020 / Business Wire
SHARESHARESHARE

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clinical research organization to oversee the initial human clinical trial, secured the clinical site, and executed an agreement with a contract manufacturing organization for cGMP manufacturing of the clinical test articles. The company plans to submit an IND in the coming months and proceed to Phase 2a clinical evaluation of LL-BMT1 in 2020.